Error loading player: No playable sources found
2525
Irritable Bowel Syndrome Clinical
Date
May 18, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AGA
Presentations:
| TREATMENT WITH THE HISTAMINE 1 RECEPTOR ANTAGONIST EBASTINE FOR NON-CONSTIPATED IRRITABLE BOWEL SYNDROME: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL |
| IS A SIMPLIFIED LOW FODMAP RESTRICTION PHASE POSSIBLE? RESULTS FROM A MULTI-CENTER, DOUBLE-BLIND, PILOT-FEASIBILITY, RANDOMIZED CONTROLLED TRIAL |
| DIFFERENCES IN DIETARY INTAKE PATTERNS CONTRIBUTE TO VARIATIONS IN THE WORLDWIDE PREVLANECE OF ROME IV IRRITABLE BOWEL SYNDROME |
| PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY OF EFFICACY OF RIFAMYCIN SV-MMX® 600 MG ADMINISTERED THREE OR TWO TIMES DAILY TO PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D) |
| EFFICACY OF A NOVEL, DISCRIMATORY P-VALUE BASED, IGG ASSAY-GUIDED ELIMINATION DIET BY IBS SUBTYPE: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED STUDY |
| APP-DELIVERED GUT-DIRECTED HYPNOTHERAPY IS SUPERIOR TO PSYCHOEDUCATION IN REDUCING SYMPTOMS ASSOCIATED WITH IRRITABLE BOWEL SYNDROME: A RANDOMISED CONTROL TRIAL |
Moderators
Mayo Clinic Scottsdale
Cleveland Clinic
Speakers
University of Michigan
Michigan Medicine
Tracks
Related Products
Reducing the Burden of GI Cancers Through Early Interventions
SOCIETY: AGA CRC prevention, Gastric cancer
Reducing CRC Incidence Through Screening and Surveillance
SOCIETY: AGA CRC screening and surveillance
